{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T13:02:01Z","timestamp":1783083721827,"version":"3.54.6"},"reference-count":16,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,6,2]],"date-time":"2023-06-02T00:00:00Z","timestamp":1685664000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,6,2]],"date-time":"2023-06-02T00:00:00Z","timestamp":1685664000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100008678","name":"Universit\u00e4t Leipzig","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100008678","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>With extended-spectrum \u03b2-lactamases (ESBLs) and CTX-M enzymes being on the rise, antimicrobial treatment of enterobacterial infections is becoming more and more challenging. Our study aimed at a molecular characterization of phenotypically ESBL-positive<jats:italic>E. coli<\/jats:italic>strains obtained from blood cultures of patients of the University Hospital of Leipzig (UKL), Germany. The presence of CMY-2, CTX-M-14 and CTX-M-15 was investigated using Streck ARM-D Kit (Streck, USA). Real-time amplifications were performed by QIAGEN Rotor-Gene Q MDx Thermocycler (QIAGEN, Thermo Fisher Scientific, USA). Antibiograms as well as epidemiological data were evaluated. Among 117 cases, 74.4% of the isolates showed a resistance to ciprofloxacin, piperacillin and ceftazidime or cefotaxime while being susceptible to imipenem\/meropenem. The proportion of ciprofloxacin resistance was significantly higher than the proportion of ciprofloxacin susceptibility. At least one of the investigated genes was detected in 93.1% of the blood culture<jats:italic>E. coli<\/jats:italic>isolates: CTX-M-15 (66.7%), CTX-M-14 (25.6%) or the plasmid-mediated ampC gene CMY-2 (3.4%). 2.6% were tested positive for two resistance genes. 94 of the corresponding stool specimens tested positive for ESBL producing<jats:italic>E. coli<\/jats:italic>(94\/112, 83.9%). 79 (79\/94, 84%)<jats:italic>E. coli<\/jats:italic>strains found in the stool samples matched with the respective patient\u2019s blood culture isolate phenotypically (MALDI-TOF, antibiogram). The distribution of resistance genes was in accordance with recent studies in Germany as well as worldwide. This study provides indications of an endogenous focus of infection and emphasize the importance of screening programs for high-risk patients.<\/jats:p>","DOI":"10.1038\/s41598-023-36240-y","type":"journal-article","created":{"date-parts":[[2023,6,2]],"date-time":"2023-06-02T10:05:33Z","timestamp":1685700333000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Extended-spectrum beta-lactamases found in Escherichia coli isolates obtained from blood cultures and corresponding stool specimen"],"prefix":"10.1038","volume":"13","author":[{"given":"Nina","family":"Doerr","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadine","family":"Dietze","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norman","family":"Lippmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arne C.","family":"Rodloff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,6,2]]},"reference":[{"key":"36240_CR1","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1586\/14787210.2014.899901","volume":"12","author":"ZA Qureshi","year":"2014","unstructured":"Qureshi, Z. A. & Doi, Y. Escherichia coli sequence type 131: Epidemiology and challenges in treatment. Expert Rev. Anti Infect. Ther. 12, 597\u2013609 (2014).","journal-title":"Expert Rev. Anti Infect. Ther."},{"key":"36240_CR2","doi-asserted-by":"publisher","first-page":"93","DOI":"10.4161\/21505594.2014.991234","volume":"6","author":"M Mora-Rillo","year":"2015","unstructured":"Mora-Rillo, M. et al. Impact of virulence genes on sepsis severity and survival in Escherichia coli bacteremia. Virulence 6, 93\u2013100 (2015).","journal-title":"Virulence"},{"key":"36240_CR3","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1016\/j.ijmm.2017.02.003","volume":"307","author":"L Micenkov\u00e1","year":"2017","unstructured":"Micenkov\u00e1, L. et al. Human Escherichia coli isolates from hemocultures: Septicemia linked to urogenital tract infections is caused by isolates harboring more virulence genes than bacteraemia linked to other conditions. Int. J. Med. Microbiol. IJMM 307, 182\u2013189 (2017).","journal-title":"Int. J. Med. Microbiol. IJMM"},{"key":"36240_CR4","doi-asserted-by":"publisher","first-page":"191","DOI":"10.3389\/fcimb.2019.00191","volume":"9","author":"AP Daga","year":"2019","unstructured":"Daga, A. P. et al. Escherichia coli bloodstream infections in patients at a University Hospital: Virulence factors and clinical characteristics. Front. Cell. Infect. Microbiol. 9, 191 (2019).","journal-title":"Front. Cell. Infect. Microbiol."},{"key":"36240_CR5","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1128\/CMR.18.4.657-686.2005","volume":"18","author":"DL Paterson","year":"2005","unstructured":"Paterson, D. L. & Bonomo, R. A. Extended-spectrum beta-lactamases: A clinical update. Clin. Microbiol. Rev. 18, 657\u2013686 (2005).","journal-title":"Clin. Microbiol. Rev."},{"key":"36240_CR6","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1128\/CMR.00023-13","volume":"26","author":"P-L Woerther","year":"2013","unstructured":"Woerther, P.-L., Burdet, C., Chachaty, E. & Andremont, A. Trends in human fecal carriage of extended-spectrum \u03b2-lactamases in the community: Toward the globalization of CTX-M. Clin. Microbiol. Rev. 26, 744\u2013758 (2013).","journal-title":"Clin. Microbiol. Rev."},{"key":"36240_CR7","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1007\/BF01647010","volume":"18","author":"A Bauernfeind","year":"1990","unstructured":"Bauernfeind, A., Grimm, H. & Schweighart, S. A new plasmidic cefotaximase in a clinical isolate of Escherichia coli. Infection 18, 294\u2013298 (1990).","journal-title":"Infection"},{"key":"36240_CR8","doi-asserted-by":"publisher","first-page":"417","DOI":"10.3389\/fmicb.2016.00417","volume":"7","author":"P Bajaj","year":"2016","unstructured":"Bajaj, P., Singh, N. S. & Virdi, J. S. Escherichia coli \u03b2-lactamases: What really matters. Front. Microbiol. 7, 417 (2016).","journal-title":"Front. Microbiol."},{"key":"36240_CR9","doi-asserted-by":"publisher","first-page":"S44","DOI":"10.1093\/jtm\/taw102","volume":"24","author":"Y Doi","year":"2017","unstructured":"Doi, Y., Iovleva, A. & Bonomo, R. A. The ecology of extended-spectrum \u03b2-lactamases (ESBLs) in the developed world. J. Travel Med. 24, S44\u2013S51 (2017).","journal-title":"J. Travel Med."},{"key":"36240_CR10","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1016\/j.jmii.2015.05.009","volume":"49","author":"C-Y Kao","year":"2016","unstructured":"Kao, C.-Y. et al. Molecular characterization of extended-spectrum \u03b2-lactamase-producing Escherichia coli and Klebsiella spp. isolates in Mongolia. J. Microbiol. Immunol. Infect. 49, 692\u2013700 (2016).","journal-title":"J. Microbiol. Immunol. Infect."},{"key":"36240_CR11","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1016\/j.vetmic.2015.10.008","volume":"200","author":"G Valenza","year":"2017","unstructured":"Valenza, G. et al. Prevalence and genetic diversity of extended-spectrum \u03b2-lactamase (ESBL)-producing Escherichia coli in nursing homes in Bavaria, Germany. Vet. Microbiol. 200, 138\u2013141 (2017).","journal-title":"Vet. Microbiol."},{"key":"36240_CR12","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1016\/j.ijantimicag.2013.07.018","volume":"42","author":"YE Ha","year":"2013","unstructured":"Ha, Y. E. et al. Epidemiology and clinical outcomes of bloodstream infections caused by extended-spectrum \u03b2-lactamase-producing Escherichia coli in patients with cancer. Int. J. Antimicrob. Agents 42, 403\u2013409 (2013).","journal-title":"Int. J. Antimicrob. Agents"},{"key":"36240_CR13","doi-asserted-by":"publisher","first-page":"e0202276","DOI":"10.1371\/journal.pone.0202276","volume":"13","author":"Y Komatsu","year":"2018","unstructured":"Komatsu, Y. et al. Molecular epidemiology and clinical features of extended-spectrum beta-lactamase- or carbapenemase-producing Escherichia coli bacteremia in Japan. PLoS ONE 13, e0202276 (2018).","journal-title":"PLoS ONE"},{"key":"36240_CR14","doi-asserted-by":"publisher","first-page":"290","DOI":"10.7883\/yoken.JJID.2016.023","volume":"70","author":"M Xu","year":"2017","unstructured":"Xu, M., Fan, Y., Wang, M. & Lu, X. Characteristics of extended-spectrum \u03b2-lactamases-producing Escherichia coli in fecal samples of inpatients of Beijing Tongren Hospital. Jpn. J. Infect. Dis. 70, 290\u2013294 (2017).","journal-title":"Jpn. J. Infect. Dis."},{"key":"36240_CR15","doi-asserted-by":"crossref","first-page":"81","DOI":"10.4103\/njcp.njcp_79_17","volume":"21","author":"G Hazirolan","year":"2018","unstructured":"Hazirolan, G. et al. Fecal carriage of extended-spectrum beta-lactamase and ampc beta-lactamase-producing enterobacteriaceae in a turkish community. Niger. J. Clin. Pract. 21, 81\u201386 (2018).","journal-title":"Niger. J. Clin. Pract."},{"key":"36240_CR16","doi-asserted-by":"publisher","first-page":"846","DOI":"10.1086\/521260","volume":"45","author":"P Reddy","year":"2007","unstructured":"Reddy, P. et al. Screening for extended-spectrum beta-lactamase-producing Enterobacteriaceae among high-risk patients and rates of subsequent bacteremia. Clin. Infect. Dis. 45, 846\u2013852 (2007).","journal-title":"Clin. Infect. Dis."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-36240-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-36240-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-36240-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,14]],"date-time":"2023-12-14T15:49:29Z","timestamp":1702568969000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-36240-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,2]]},"references-count":16,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["36240"],"URL":"https:\/\/doi.org\/10.1038\/s41598-023-36240-y","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6,2]]},"assertion":[{"value":"27 May 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 May 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 June 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"8940"}}